A Phase 1b Open-Label, Dose Escalation Study of PRTX-100 in Adult Patients With Persistent/Chronic Immune Thrombocytopenia

Trial Profile

A Phase 1b Open-Label, Dose Escalation Study of PRTX-100 in Adult Patients With Persistent/Chronic Immune Thrombocytopenia

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 07 Jun 2017

At a glance

  • Drugs Staphylococcal-protein-A (Primary)
  • Indications Immune thrombocytopenic purpura
  • Focus Adverse reactions
  • Sponsors Protalex
  • Most Recent Events

    • 07 Jun 2017 According to a Protalex media release, the company has started patients screening in the United Kingdom. With this expansion, the company now has more than 20 sites worldwide open for patient enrollment.
    • 26 Apr 2017 Planned End Date changed from 1 Nov 2017 to 1 May 2018.
    • 26 Apr 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Dec 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top